SNDX
Syndax Pharmaceuticals, Inc.NASDAQHealthcare$25.15+5.32%ClosedMarket Cap: $2.22B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
32.55
P/S
12.43
EV/EBITDA
-10.66
DCF Value
$15.48
FCF Yield
-15.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.0%
Operating Margin
-158.4%
Net Margin
-165.6%
ROE
-206.6%
ROA
-53.9%
ROIC
-66.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $68.5M | 102.3% | $-62.5M | $-68.0M | $-0.78 | — |
| FY 2025 | $172.4M | 96.0% | $-273.1M | $-285.4M | $-3.30 | — |
| Q3 2025 | $45.9M | 86.1% | $-57.4M | $-60.7M | $-0.70 | — |
| Q2 2025 | $38.0M | 96.6% | $-69.4M | $-71.8M | $-0.83 | — |
| Q1 2025 | $20.0M | 95.6% | $-83.8M | $-84.8M | $-0.99 | — |
| Q4 2024 | $7.7M | 100.0% | $-96.4M | $-94.2M | $-1.10 | — |
| FY 2024 | $23.7M | 96.5% | $-339.7M | $-318.8M | $-3.73 | — |
| Q3 2024 | $12.5M | 100.0% | $-89.6M | $-84.1M | $-0.98 | — |
| Q2 2024 | $3.5M | 100.0% | $-74.2M | $-68.1M | $-0.80 | — |
| Q1 2024 | $0.00 | NaN% | $-79.5M | $-72.4M | $-0.85 | — |
| Q4 2023 | $0.00 | NaN% | $-77.9M | $-72.5M | $-1.00 | — |
| FY 2023 | $0.00 | NaN% | $-230.0M | $-209.4M | $-2.98 | — |